QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
QQQ   353.15 (+1.24%)
AAPL   180.57 (+1.55%)
MSFT   325.26 (+0.58%)
META   264.58 (+0.37%)
GOOGL   122.14 (-0.29%)
AMZN   124.25 (+2.49%)
TSLA   234.86 (+4.58%)
NVDA   385.10 (+2.76%)
NIO   7.79 (+0.39%)
BABA   86.14 (+1.01%)
AMD   121.05 (+2.73%)
T   16.07 (-0.25%)
F   13.58 (-0.07%)
MU   65.32 (-2.59%)
CGC   0.69 (-4.14%)
GE   106.06 (-0.02%)
DIS   92.53 (+0.01%)
AMC   4.68 (-1.06%)
PFE   39.09 (+0.51%)
PYPL   64.24 (+0.31%)
NFLX   409.37 (+2.40%)
NASDAQ:ASLN

ASLAN Pharmaceuticals (ASLN) Competitors

$3.84
-0.23 (-5.65%)
(As of 06/8/2023 ET)
Compare
Today's Range
$3.72
$4.22
50-Day Range
$2.62
$4.59
52-Week Range
$1.70
$4.95
Volume
105,860 shs
Average Volume
47,403 shs
Market Capitalization
$53.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.00

ASLN vs. NBRV, VIRX, CARM, MBIO, HCWB, NRXP, PRAX, ASMB, BIOR, and ANEB

Should you be buying ASLAN Pharmaceuticals stock or one of its competitors? The main competitors of ASLAN Pharmaceuticals include Nabriva Therapeutics (NBRV), Viracta Therapeutics (VIRX), Carisma Therapeutics (CARM), Mustang Bio (MBIO), HCW Biologics (HCWB), NRx Pharmaceuticals (NRXP), Praxis Precision Medicines (PRAX), Assembly Biosciences (ASMB), Biora Therapeutics (BIOR), and Anebulo Pharmaceuticals (ANEB). These companies are all part of the "medical" sector.

ASLAN Pharmaceuticals vs.

ASLAN Pharmaceuticals (NASDAQ:ASLN) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, community ranking, dividends, profitability and media sentiment.

Nabriva Therapeutics received 201 more outperform votes than ASLAN Pharmaceuticals when rated by MarketBeat users. However, 62.54% of users gave ASLAN Pharmaceuticals an outperform vote while only 62.38% of users gave Nabriva Therapeutics an outperform vote.

CompanyUnderperformOutperform
ASLAN PharmaceuticalsOutperform Votes
192
62.54%
Underperform Votes
115
37.46%
Nabriva TherapeuticsOutperform Votes
393
62.38%
Underperform Votes
237
37.62%

In the previous week, ASLAN Pharmaceuticals and ASLAN Pharmaceuticals both had 1 articles in the media. ASLAN Pharmaceuticals' average media sentiment score of 0.47 beat Nabriva Therapeutics' score of 0.00 indicating that ASLAN Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ASLAN Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Nabriva Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

ASLAN Pharmaceuticals has a beta of 1.83, indicating that its stock price is 83% more volatile than the S&P 500. Comparatively, Nabriva Therapeutics has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500.

31.6% of ASLAN Pharmaceuticals shares are held by institutional investors. Comparatively, 0.2% of Nabriva Therapeutics shares are held by institutional investors. 4.7% of ASLAN Pharmaceuticals shares are held by insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

ASLAN Pharmaceuticals presently has a consensus price target of $16.00, indicating a potential upside of 316.67%. Given ASLAN Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe ASLAN Pharmaceuticals is more favorable than Nabriva Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ASLAN Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00
Nabriva Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

ASLAN Pharmaceuticals has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. ASLAN Pharmaceuticals' return on equity of -315.43% beat Nabriva Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ASLAN Pharmaceuticals N/A -315.43% -83.80%
Nabriva Therapeutics -148.11% -365.53% -135.81%

ASLAN Pharmaceuticals has higher earnings, but lower revenue than Nabriva Therapeutics. ASLAN Pharmaceuticals is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ASLAN PharmaceuticalsN/AN/A-$51.38 million-$4.08-0.94
Nabriva Therapeutics$36.94 million1.30-$57.19 million-$19.20-0.08

Summary

ASLAN Pharmaceuticals beats Nabriva Therapeutics on 13 of the 16 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ASLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ASLN vs. The Competition

MetricASLAN PharmaceuticalsBiotechnology IndustryMedical SectorNASDAQ Exchange
Market Cap$53.57M$578.08M$4.62B$6.27B
Dividend YieldN/A2.69%2.37%6.44%
P/E Ratio-0.94319.20111.0313.34
Price / SalesN/A26,213.563,466.81100.76
Price / CashN/A10.9191.55107.03
Price / Book6.404.834.725.31
Net Income-$51.38M$86.46M$117.72M$192.96M
7 Day Performance-8.35%7.45%2.74%4.03%
1 Month Performance-14.67%3.11%2.13%5.34%
1 Year Performance102.11%111.48%11.17%1.86%

ASLAN Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NBRV
Nabriva Therapeutics
0 of 5 stars
$1.61
+3.9%
N/A-72.4%$51.54M$36.94M-0.0872
VIRX
Viracta Therapeutics
2.0895 of 5 stars
$1.37
-6.2%
$8.00
+483.9%
-46.3%$52.62MN/A-1.0224High Trading Volume
CARM
Carisma Therapeutics
2.0873 of 5 stars
$4.99
-3.7%
$10.00
+100.4%
N/A$50.80M$40M-1.27N/A
MBIO
Mustang Bio
2.2469 of 5 stars
$6.21
+19.7%
$43.33
+597.8%
-37.6%$50.67MN/A-0.60102High Trading Volume
HCWB
HCW Biologics
2.5042 of 5 stars
$1.49
-9.7%
$8.50
+470.5%
-8.4%$53.48M$6.72M-2.8144News Coverage
Gap Up
NRXP
NRx Pharmaceuticals
2.3444 of 5 stars
$0.70
flat
$3.00
+328.6%
-19.2%$50.09MN/A-1.232
PRAX
Praxis Precision Medicines
2.2986 of 5 stars
$0.87
-13.0%
$10.50
+1,110.0%
-45.1%$53.89MN/A-0.22139
ASMB
Assembly Biosciences
2.5339 of 5 stars
$0.95
-3.1%
$2.17
+128.1%
-47.4%$49.51M$6.25M-0.52102
BIOR
Biora Therapeutics
1.7006 of 5 stars
$4.58
+7.5%
$3,750.00
+81,777.7%
-98.9%$54.32M$310,000.00-0.97642
ANEB
Anebulo Pharmaceuticals
2.1459 of 5 stars
$2.13
-10.5%
$7.00
+228.6%
-27.7%$54.59MN/A-4.532Gap Up

Related Companies and Tools

This page (NASDAQ:ASLN) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -